Literature DB >> 32762609

A Novel Hypothesis for Original Antigenic Sin in the Severe Disease of SARS-CoV-2 Infection.

Heinz Kohler1, Peter Nara2.   

Abstract

In this hypothesis, we address the biological/immunological pathway leading to severe disease or death after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The underlying immune response is described with "original antigenic sin" (OAS) whereby previous infections influence the response to future virus encounters. We cite evidence for OAS-induced immunopathology in HIV-1 disease. We hypothesize that similar immune abnormalities can occur after infection with SARS-CoV-2. This hypothesis is supported by recent analysis of the antibodies in infected patients demonstrating serological and B cell abnormalities. The concept of symmetrical clonal regulation developed earlier for the immune network illustrates the pathway suggested by our hypothesis and may be helpful to develop strategies avoiding severe coronavirus disease 2019.

Entities:  

Keywords:  SARS-CoV-2; coronavirus; original antigenic sin

Mesh:

Substances:

Year:  2020        PMID: 32762609     DOI: 10.1089/mab.2020.0029

Source DB:  PubMed          Journal:  Monoclon Antib Immunodiagn Immunother        ISSN: 2167-9436


  3 in total

1.  Evaluation of Antibody Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic Assessment of New IgM/IgG ELISA Kits.

Authors:  Hadeel T Al-Jighefee; Hadi M Yassine; Gheyath K Nasrallah
Journal:  Pathogens       Date:  2021-02-03

2.  Evidence for deleterious effects of immunological history in SARS-CoV-2.

Authors:  Sanjana R Sen; Emily C Sanders; Alicia M Santos; Keertna Bhuvan; Derek Y Tang; Aidan A Gelston; Brian M Miller; Joni L Ricks-Oddie; Gregory A Weiss
Journal:  PLoS One       Date:  2022-08-24       Impact factor: 3.752

Review 3.  A systematic review and meta-analysis of the sensitivity of antibody tests for the laboratory confirmation of COVID-19.

Authors:  Nigel A Makoah; Thomas Tipih; Matefo M Litabe; Mareza Brink; Joseph B Sempa; Dominique Goedhals; Felicity J Burt
Journal:  Future Virol       Date:  2021-12-15       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.